Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen

International Immunopharmacology

Volumn 2, Issue 13-14, 2002, Pages 1887-1894

  Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bradykinin; Endothelial cells; Kininogen; Tumors

Indexed keywords

BRADYKININ; HIGH MOLECULAR WEIGHT KININOGEN; KININOGEN; KININOSTATIN; MONOCLONAL ANTIBODY; PLASMA KALLIKREIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CHICKEN; COLON CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; FETUS MEMBRANE; HUMAN; HUMAN CELL; HYBRIDOMA; ISOGRAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; XENOGRAFT; ANIMAL; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS;

EID: 0036891757     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00173-X     Document Type: Review

References (17)

1. Lin Y., Harris R.B., Yan W., McCrae K.R., Zhang H., Colman R.W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood. 90:1997;690-697.
2. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J.et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J. Clin. Invest. 100:1997;1481-1487.
3. Joseph K., Ghebrehiwet B., Peerschke E.I., Reid K.B., Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc. Natl. Acad. Sci. U. S. A. 93:1996;8552-8557.
4. Hasan A.A.K., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3615-3620.
5. Shariat-Madar Z., Mahdi F., Schmaier A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277:2002;17962-17969.
6. Ichinose A., Fujikawa K., Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261:1986;3486-3489.
7. Hauert J., Nicoloso G., Schleuning W.D., Bachmann F., Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin functions: a molecular analysis of factor XII and prekallikrein-dependent fibrinolysis. Blood. 73:1989;994-999.
8. Colman R.W., Jameson B.A., Lin Y., Johnson D., Mousa S.A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 95:2000;543-550.
9. Guo Y.L., Wang S., Colman R.W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21:2001;1427-1433.
10. Colman R.W., Pixley R.A., Sainz I.M., Song J.S., Isordia-Salas I.et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high molecular weight kininogen. J. Thromb. Haemost. 2003;. [in press].
11. Colman R.W., Schmaier A.H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 90:1997;3819-3843.
12. Asakura S., Hurley R.W., Skorstengaard K., Ohkubo I., Mosher D.F. Inhibition of cell adhesion by high molecular weight kininogen. J. Cell Biol. 116:1992;465-476.
13. Parenti A., Morbidelli L., Ledda F., Granger H.J., Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 15:2001;1487-1489.
14. Pixley R.A., Sheng N., Johnson D.H., Colman R.W. Domain 5 of high molecular weight kininogen (HK) is responsible for the binding to the urokinase receptor. Blood. 94:1999;223a. [abstract].
15. Kimura M., Sueyoshi T., Takada K., Tanaka K., Morita T., Iwanaga S. Isolation and characterization of ornitho-kininogen. [published erratum appears in Eur. J. Biochem. 1988 Mar 15;172(3):784] Eur. J. Biochem. 168:1987;493-501.
16. Song J.S., Sainz I.M., Cosenza S.C., Reddy E.P., Colman R.W. Inhibition of tumor angiogenesis in vivo by monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Thromb. Haemost. 2001;OC1674. [Suppl., Abstract].
17. Sainz I., Long W.K., Colman R.W. Effect of monoclonal antibodies to high molecular weight kininogen (HK) on growth and neovascularization of murine syngenetic tumors. Fed. Proc. 15:2001;A459. [Abstract].